Potassium News and Research

RSS

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

Rice consumption improves overall diet and reduces obesity and Type II diabetes

According to recent research published in the October issue of the Journal of the American Dietetic Association (JADA), eating rice helps improve overall diet and potentially reduces the risk for many chronic diseases, including obesity, cardiovascular disease and Type II diabetes.

12 Oct 2009

Ipsen signs exclusive marketing agreement to produce and distribute Braintree's BLI-800 for colonic cleansing

Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group and Braintree Laboratories, Inc., a US-based company specializing in the development, manufacturing and marketing of specialty pharmaceuticals, announced today the signature of an agreement for the exclusive manufacturing, marketing and distribution rights of Braintree’s proprietary formulation BLI-800 in colonic cleansing before colonoscopy, the best diagnostic procedure for colorectal cancer screening.

9 Oct 2009

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

Relypsa, Inc., today announced the initiation of patient enrollment in the PEARL-HF study, a Phase 2b clinical trial of the company’s lead compound, RLY5016. A novel potassium binder designed for chronic use, RLY5016 is being evaluated in the prevention and treatment of hyperkalemia, for which there are no current satisfactory treatments.

7 Oct 2009

Government handout of samples of potassium iodide helps to boost sales for Nukepills.com

The recent localized government handout of samples of potassium iodide has sky-rocketed sales for online merchant Nukepills.com. Recent retail orders of Iosat(TM) Potassium Iodide have increased by almost 400% and wholesale orders to vendors and medical facilities have surged as well for the authorized national distributor.

7 Oct 2009

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced positive results from its Phase 2 clinical study evaluating luliconazole, one of the most potent and broad spectrum topical antifungal agents, in patients with tinea pedis (athlete's foot). The study was designed to assess the effectiveness of 1% luliconazole cream applied once daily for 14 days compared with once daily for 28 days.

6 Oct 2009

Pepsico's initiative to reduce obesity, joins HWCF

PepsiCo, Inc., one of the world's largest food and beverage companies, today announced that it will expand its existing efforts to help reduce obesity in the United States by joining the Healthy Weight Commitment Foundation (HWCF).

6 Oct 2009

Lupin grants Salix exclusive rights to its bioadhesive drug delivery technology for use with rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of September 30, 2009 Lupin Ltd. granted Salix the exclusive right in the United States to its bioadhesive drug delivery technology for use with rifaximin. Salix and Lupin have entered into a development, commercialization and license agreement under which the two companies will collaborate in the development and commercialization of a product incorporating rifaximin and utilizing Lupin’s proprietary technology.

5 Oct 2009

Michelle’s Miracle raises $750,000 in its first tranche of Series A funding

Michelle’s Miracle, Inc the leading provider of tart cherry nutraceutical products announced that it has closed its first tranche of Series A funding after raising approximately $750,000 in equity.

30 Sep 2009

Research study links high-fructose diet to increased blood pressure in men

A high-fructose diet raises blood pressure in men, while a drug used to treat gout seems to protect against the blood pressure increase, according to research reported at the American Heart Association's 63rd High Blood Pressure Research Conference.

24 Sep 2009

Nukepills replenishes its stock of N95 face masks for flu season

Nukepills.com today announced the replenishment of its stock of N95 Particulate Masks just in time for the upcoming flu season. A deluge of online orders in May of this year, in response to media stories of the Swine Flu Virus (H1N1), depleted the company's large inventory in just a few days.

23 Sep 2009

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).

23 Sep 2009

Preventing nerve cell death in diabetics

Dennis Paul, PhD, Associate Professor of Pharmacology, and Harry Gould, MD, PhD, the Tom Benson Professor of Neurology at LSU Health Sciences Center New Orleans, have been awarded one of two scientific research grants made in 2009 by The Neuropathy Association. The $80,000 grant will fund research to learn how to prevent nerve cell death in people with uncontrolled or untreated diabetes resulting in neuropathy.

23 Sep 2009

Women have higher incidence of stroke and mortality than men

Even though the incidence of atrial fibrillation is higher in men than women, a review of past studies and medical literature completed by cardiac experts at Rush University Medical Center shows that women are more likely than men to experience symptomatic attacks, a higher frequency of recurrences, and significantly higher heart rates during atrial fibrillation, which increases the risk of stroke.

23 Sep 2009

Study reveals that KCNE2 and KCNQ1 mutations can results in thyroid dysfunction

Genes previously known to be essential to the coordinated, rhythmic electrical activity of cardiac muscle -- a healthy heartbeat -- have now also been found to play a key role in thyroid hormone (TH) biosynthesis, according to Weill Cornell Medical College researchers.

21 Sep 2009

Texas attemps to offer access to quality dialysis care

Local officials, physicians and patients in need of local dialysis care expressed encouragement over what appears to be a thawing of a certification logjam of dialysis facilities across the state of Texas, though remain concerned over 38 which still remain idling to many for more than a year – to the detriment of local jobs and patients in dire need of better access to quality dialysis care.

18 Sep 2009

FDA approves Valturna tablets for treating high blood pressure

The US Food and Drug Administration (FDA) has approved Valturna((R)) (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure.

18 Sep 2009

Skinny Water now available at Gristedes supermarkets

Skinny Nutritional Corp. the maker of Skinny Water® and a leader in the zero-calorie enhanced water category, announced today that Skinny Water® is now available at all Gristedes locations.

18 Sep 2009

Phase 3 results of TARGET 1 and TARGET 2 clinical trials released

Salix Pharmaceuticals, Ltd. today announced the successful outcome of two Phase 3, randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).

14 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009